The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
De novo design of covalent bonding peptides for target protein
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A. C., Park, Y.-J., et al. (2020) · Science · doi:10.1126/science.abd9909 · Cited by 742
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535 · cited 3×
“We fi rst analyzed the binding interfaces of hACE2 and Omi-cron RBD extracted from the solved crystal structure (PDB ID: 7TN0) [18].”
Research works printed but not linked: 37
- Day, 2021, Multidisciplinary approaches identify compounds that bind to human ACE2 or SARS-CoV-2 spike protein as candidates to block SARS-CoV-2-ACE2 receptor interactions, mBio, 12, 10.1128/mBio.03681-20 · DOI
- Sun, 2021, Aptamer blocking strategy inhibits SARS-CoV-2 virus infection, Angew Chem Int Ed Engl, 60, 10266, 10.1002/anie.202100225 · DOI · Paper page
- Han, 2020, Computational design of ACE2-based peptide inhibitors of SARS-CoV-2, ACS Nano, 14, 5143, 10.1021/acsnano.0c02857 · DOI · Paper page
- Qin, 2021, Covalent bonding aptamer with enhanced SARS-CoV-2 RBD-ACE2 blocking and pseudovirus neutralization activities, ChemRxiv
- Uraki, 2022, Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2, Nature, 607, 119, 10.1038/s41586-022-04856-1 · DOI · Paper page
- Tang, 2022, AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2, Biomolecules, 12, 746, 10.3390/biom12060746 · DOI
- Han, 2022, Covalently engineered protein minibinders with enhanced neutralization efficacy against escaping SARS-CoV-2 variants, J Am Chem Soc, 144, 5702, 10.1021/jacs.1c11554 · DOI
- Cui, 2012, Biomimetic peptide nanosensors, Acc Chem Res, 45, 696, 10.1021/ar2002057 · DOI
- Ling, 2020, In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2, Peptides, 130, 10.1016/j.peptides.2020.170328 · DOI
- Zhang, 2020, The first-in-class peptide binder to the SARS-CoV-2 spike protein, bioRxiv
- Pomplun, 2021, De novo discovery of high-affinity peptide binders for the SARS-CoV-2 spike protein, ACS Cent Sci, 7, 156, 10.1021/acscentsci.0c01309 · DOI
- Zhu, 2022, A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair, J Hazard Mater, 425, 10.1016/j.jhazmat.2021.127923 · DOI
- Yin, 2021, Rational design of potent peptide inhibitors of the PD-1:PD-L1 interaction for cancer immunotherapy, J Am Chem Soc, 143, 18536, 10.1021/jacs.1c08132 · DOI · Paper page
- Berdan, 2021, Covalent peptides and proteins for therapeutics, Biorg Med Chem, 29, 10.1016/j.bmc.2020.115896 · DOI
- Hoppmann, 2016, Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53–Mdm4, Chem Commun, 52, 5140, 10.1039/C6CC01226D · DOI
- Narayanan, 2015, Sulfonyl fluorides as privileged warheads in chemical biology, Chem Sci, 6, 2650, 10.1039/C5SC00408J · DOI · Paper page
- Marze, 2018, Efficient flexible backbone protein–protein docking for challenging targets, Bioinformatics, 34, 3461, 10.1093/bioinformatics/bty355 · DOI · Paper page
- Sedan, 2016, Peptiderive server: Derive peptide inhibitors from protein–protein interactions, Nucleic Acids Res, 44, W536, 10.1093/nar/gkw385 · DOI
- Gambini, 2020, Stability and cell permeability of sulfonyl fluorides in the design of Lys-covalent antagonists of protein-protein interactions, ChemMedChem, 15, 2176, 10.1002/cmdc.202000355 · DOI
- London, 2014, Covalent docking of large libraries for the discovery of chemical probes, Nat Chem Biol, 10, 1066, 10.1038/nchembio.1666 · DOI · Paper page
- Martin, 2019, Characterising covalent warhead reactivity, Bioorg Med Chem, 27, 2066, 10.1016/j.bmc.2019.04.002 · DOI
- Jones, 2020, Structure-based design and analysis of SuFEx chemical probes, RSC Med Chem, 11, 10, 10.1039/C9MD00542K · DOI
- Lamiable, 2016, PEP-FOLD3: Faster de novo structure prediction for linear peptides in solution and in complex, Nucleic Acids Res, 44, W449, 10.1093/nar/gkw329 · DOI · Paper page
- Hanoulle, 2006, A new functional, chemical proteomics technology to identify purine nucleotide binding sites in complex proteomes, J Proteome Res, 5, 3438, 10.1021/pr060313e · doi:10.1021/pr060313e
- Liu, 2021, Ultrasensitive detection of endocrine disruptors via superfine plasmonic spectral combs, Light Sci Appl, 10, 181, 10.1038/s41377-021-00618-2 · doi:10.1038/s41377-021-00618-2
- Almehdi, 2021, SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies, Infection, 49, 855, 10.1007/s15010-021-01677-8 · DOI
- Koyama, 2020, Variant analysis of SARS-CoV-2 genomes, Bull World Health Organ, 98, 495, 10.2471/BLT.20.253591 · DOI · Paper page
- Viana, 2022, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa, Nature, 603, 679, 10.1038/s41586-022-04411-y · DOI · Paper page
- Iketani, 2022, Antibody evasion properties of SARS-CoV-2 Omicron sublineages, Nature, 604, 553, 10.1038/s41586-022-04594-4 · DOI · Paper page
- Odolczyk, 2022, Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2, Front Mol Biosci, 9, 10.3389/fmolb.2022.983014 · DOI
- Wang, 2022, In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery, J Med Virol, 94, 1766, 10.1002/jmv.27540 · doi:10.1002/jmv.27540
- Wang, 2021, An overview of kinase downregulators and recent advances in discovery approaches, Signal Transduct Targeted Ther, 6, 423, 10.1038/s41392-021-00826-7 · DOI
- Kagami, 2023, The ACPYPE web server for small-molecule MD topology generation, Bioinformatics, 39, 10.1093/bioinformatics/btad350 · DOI · Paper page
- Kumari, 2014, g_mmpbsa—a GROMACS tool for high-throughput MM-PBSA calculations, J Chem Inf Model, 54, 1951, 10.1021/ci500020m · DOI · Paper page
- Olsson, 2011, PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions, J Chem Theor Comput, 7, 525, 10.1021/ct100578z · DOI · Paper page
- Orsburn, 2021, Proteome discoverer—a community enhanced data processing suite for protein informatics, Proteomes, 9, 15, 10.3390/proteomes9010015 · DOI · Paper page
- Takashita, 2022, Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2, N Engl J Med, 386, 1475, 10.1056/NEJMc2201933 · DOI
Metadata
- Authors
- Zhou, X., Zhu, Q., Zheng, A., Xue, B., Wang, Q., Chin, L. K., Jiang, J., & He, M.
- Venue
- hLife
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 2
- Issue
- 12
- Pages
- 641-652
- ISSN
- 2949-9283
- Cited by
- 36
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Natural Science Foundation of China (52091541)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: De novo design of covalent bonding peptides for target protein. https://app.cochat.ai/papers/10.1016/j.hlife.2024.07.007
- The paper
- Zhou, X., Zhu, Q., Zheng, A., Xue, B., Wang, Q., Chin, L. K., Jiang, J., & He, M. (2024). De novo design of covalent bonding peptides for target protein. hLife. https://doi.org/10.1016/j.hlife.2024.07.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.